Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xialiqi capsules for benign prostatic hyperplasia
ChiCTR1900022393Phase 4Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of letrozole in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: International Prostate Symptom Score. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
letrozole
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on ChiCTR1900022393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022393.